Johnson & Johnson launches public welfare project for functional cure of blood tumors

September is International Blood Tumor Awareness Month, and the themed public welfare project of "Ten Years of Promise, together for a New Life" blood tumor functional cure initiated by Johnson & Johnson and supported by People's Good Doctors officially kicked off in the ancient capital of Xi'an, Shaanxi province in Northwest China. 

The themed public welfare project of "Ten Years of Promise, together for a New Life" for functional cure of blood tumors has been officially launched on Thursday. 

The project focuses on the desire of blood tumor patients to achieve higher treatment goals, pursue "functional cure", and stay with their families for a long time. While carrying out popular science education and guiding patients to undergo standardized treatment in the long term, it systematically builds customized activities that are helpful for daily disease management and prognosis rehabilitation, taking into account the concentration of elderly blood tumor patients. 

And through the exemplary power of "functional healing", the project encourages more patients to actively fight against cancer, combine scientific spirit with humanistic feelings, and empower patients to enjoy a better life again. 

Hematological tumors are malignant tumors originating from the hematopoietic system, mainly including leukemia, multiple myeloma and lymphoma. 

In recent years, with the rapid development of clinical diagnosis and treatment and continuous breakthroughs in innovative drug research and development, multiple myeloma and lymphoma, two common hematological malignancies in clinical practice, have gradually become slowly managed. More and more patients have not only broken the five-year survival barrier, but also achieved high-quality survival of eight, ten, or even longer. Functional cure is becoming their achievable treatment goal.

Taking multiple myeloma as an example, the average survival time of patients has reached 7-8 years, exceeding the goal of achieving a 5-year overall cancer survival rate of 46.6% by 2030 proposed in the "Healthy China 2030 Plan". 

Xin Shaohua, patient representative and president of the Mutual Aid Association for Multiple Myeloma Patients, delivered a speech at the event launch ceremony. 

Xin Shaohua, who is 70 years old this year, is not only a patient who has been fighting multiple myeloma for 20 years, but also a science popularization worker who has been committed to popularizing knowledge about myeloma for many years. 

He said that with the unremitting efforts of doctors and the full support of his family, he was lucky to have survived from three to five years to five to ten years, and later achieved functional cure. Now he is just like a normal person. 

“I hope to make patients and their families aware of this disease as much as possible, so that they can treat it correctly. I always believe that with the arrival of new drugs and in-depth research on this disease, more and more patients will have longer survival time and better quality of life, and we will be closer to 'cure',” Xin said. 

Professor Liu Li, director of Shaanxi Clinical Research Center for Hematology, delivered a speech at the event ceremony. 

Professor Liu Li said that with the deepening of the aging of the population, the incidence rate of multiple myeloma has increased year by year. The growth of treatment demand has promoted the progress of clinical diagnosis and treatment, and has made a series of gratifying achievements. 

“With the innovation of treatment methods, some patients have achieved complete remission or above after receiving standardized treatment, combined with autologous stem cell transplantation and consolidation therapy. The progression free survival period can reach about five years, approaching a state of functional cure,” Liu said. 

Huang Chen, president of Johnson & Johnson Innovative Pharmaceuticals China, gave the speech at the event ceremony.

When it comes to the original intention of initiating this project, Huang Chen, president of Johnson & Johnson Innovative Pharmaceuticals China, said that Johnson & Johnson has been deeply rooted in the field of oncology for 20 years, continuously providing multiple solutions for patients at different stages of the disease through product iteration, hoping to promote chronic management of multiple myeloma, lymphoma and other diseases, and give more patients the opportunity to move towards functional cure. 

Huang said that Johnson & Johnson will continue to work together with multiple parties to explore innovative cancer patient service models with Chinese characteristics, benefiting more patients and extending the 'road to cure' to more waiting families. 

The event also innovatively created the customized Eight Section Brocade Rehabilitation Exercise for blood tumor patients, allowing them to bring disease rehabilitation training into their daily lives. Through soft and coherent movements, it soothes the body and mind, enhances immunity, and helps with functional healing. 

The end.